Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Reducing the Effects of Aging on Cognition With Therapeutic Intervention of an Oral Nutrient (REACTION): A Pilot Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04147624
Recruitment Status : Completed
First Posted : November 1, 2019
Last Update Posted : January 25, 2023
American Academy of Neurology
Information provided by (Responsible Party):
Christian Camargo, University of Miami

Brief Summary:

The purpose of this research is to assess the feasibility (e.g., recruitment rate, adherence rate and retention rate) of a clinical trial using virtual assessments to investigate the effect of a 6-month administration of a specific multi-nutrient oral supplement on cognitive aging.

The study will also test whether a 6-month daily intake of a specific multinutrient can delay or reverse the effects of normal cognitive aging on other cognition domains as well as quality of life as measured by virtual assessments.

Condition or disease Intervention/treatment Phase
Cognitive Decline Drug: Souvenaid Other: Placebo Phase 2

Detailed Description:
Participants with cognitive aging who meet the eligibility criteria are provided study information and scheduled for a screening visit via virtual encounter. At the screening visit, participants meeting criteria are enrolled, and a baseline visit is scheduled (same day, or separately.) The participants are then randomized to either the test product (specific multi-nutrient) or placebo. Study parameters will be assessed at baseline, and 6 months via a virtual online platform. Patients will be contacted monthly via telephone to promote compliance and monitor progress. An optional sample of blood may be provided by the participant if willing to participated in this optional sub-study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: REACTION Trial: Medical Nutrition in Cognitive Aging, a Double-blind Controlled 6-month Study
Actual Study Start Date : June 4, 2021
Actual Primary Completion Date : December 2, 2022
Actual Study Completion Date : December 2, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment Group
Participants in the treatment group will receive 125 mL of Souvenaid taken by mouth, once daily, for 6 consecutive months.
Drug: Souvenaid
Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.

Placebo Comparator: Placebo Group
Participants in the treatment group will receive 125 mL of iso-caloric placebo taken by mouth, once daily, for 6 consecutive months.
Other: Placebo
The Placebo used in this study is an oral beverage vitamin mixture containing Vitamins A, B1, B2, B3 and B5.

Primary Outcome Measures :
  1. Successful recruitment rate [ Time Frame: Baseline ]
    50% or more of those who fulfill the criteria and are invited to participate

  2. Successful recruitment time [ Time Frame: Baseline ]
    <110% of planned time

  3. Successful adherence to the intervention [ Time Frame: 6 months ]
    80% or more of the test product is consumed

  4. Successful Retention rate [ Time Frame: 6 months ]

    Less than 30% of the participants drop-out; Tracking the percentage of participants in the "Per-Protocol" population (i.e., no protocol deviation) less than 30% of the participants drop-out

    Tracking the percentage of participants in the "Per-Protocol" population (i.e., no protocol deviation)

  5. Overall feasibility of this study will be assessed [ Time Frame: 6 months ]
    Will take into account all feasibility parameters

Secondary Outcome Measures :
  1. Rey Auditory Verbal Learning Task (RAVLT) or WHO/UCLA Auditory Verbal Learning Task (AVLT) [ Time Frame: Baseline, 6 months ]
    The test takes 10-15 minutes plus a 30-minute delay during which time other measures can be done.

  2. Digit Span (WAIS-IV) [ Time Frame: Baseline, 6 months ]
    measures attention and working memory using exercises that require participants to recite a A series of progressively longer sequence of numbers in forwards, backwards and sequencing order.

  3. The Oral Trail Making Test B [ Time Frame: Baseline, 6 months ]
    (TMT-B) assesses working memory and cognitive flexibility. Participants are asked to verbally alternate between letters and numbers in sequential order as quickly as possible.

  4. Matrix reasoning from the Test My Brain (TMB) research battery [ Time Frame: Baseline, 6 months ]
    The task provides a measure of fluid intelligence and non-verbal reasoning. It is based on a well-validated and widely used matrix reasoning tasks but adapted for virtual administration.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. English or Spanish speaking participants considered to have age-related cognitive decline based on the following criteria:

    A) RBANS (Verbal Memory Retention) A score ≥70% on list learning retention AND ≥80% on story memory retention and B) Subjective Cognitive Decline (SCD) 9-item brief screening tool score within the 25th percentile (SCD =1) and 75th percentile (SCD = 6) and C) MoCA ≥24

  2. Age 55-89
  3. Written informed consent provided by participant

Exclusion Criteria:

  1. Enrollment in any other clinical trial within 30 days prior to participation
  2. Major Neurocognitive Disorder ("Dementia") according to the Diagnostic and Statistical Manual of Mental Disorders 5th Edition and/or NIAA Criteria
  3. Use of any AD medication (e.g., cholinesterase inhibitors, NMDA antagonists), or OTC supplements or cognitive/memory enhancers
  4. Use of omega-3 fatty acids in the 30 days prior to participation
  5. Intake of Vitamins B6 and B12, folate, Vitamins C and E > 300% RDI in the 24 days prior to participation
  6. Concurrent major medical or neurological illness
  7. Prior clinical history of stroke
  8. History of substance abuse (e.g., alcohol, drugs)
  9. Untreated Major Depressive Disorder that has not been in remission for at least 6 months prior to participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04147624

Layout table for location information
United States, Florida
University of Miami
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
American Academy of Neurology
Layout table for investigator information
Principal Investigator: Christian Camargo, MD University of Miami
Layout table for additonal information
Responsible Party: Christian Camargo, Assistant Professor, University of Miami Identifier: NCT04147624    
Other Study ID Numbers: 20190750
First Posted: November 1, 2019    Key Record Dates
Last Update Posted: January 25, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Christian Camargo, University of Miami:
Cognitive Aging
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders